Armed with $55 million in series A funds and a U.S. government contract, Cambridge, Mass.-based Red Queen Therapeutics Inc. launched operations this week, with plans to advance its novel stapled lipopeptide platform, which creates new antiviral therapies that do not rely on the immune system to work.
The U.S. Department of Health and Human Services has discovered viral maturation inhibitors and their prodrugs reported to be useful for the treatment of HIV infection.
Incyte Corp. has synthesized diacylglycerol kinase α (DGK-α) and/or diacylglycerol kinase ζ (DGK-ζ) inhibitors reported to be useful for the treatment of cancer.
The University of Florida has prepared and tested PPARγ agonists reported to be useful for the treatment of diabetes, hyperparathyroidism, metabolic syndrome, multiple myeloma, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), obesity, osteoporosis and Paget disease, among others.
Angel Pharmaceuticals Co. Ltd. has described protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Researchers from Wayshine Biopharm Holding Ltd. published new data regarding the preclinical systemic pharmacokinetics (PK), dose proportionality, and central nervous system (CNS) distribution of the novel ataxia telangiectasia mutated (ATM) inhibitor WSD-0628, being developed for the treatment of brain tumors.
Anivive Lifesciences Inc., a One Health technology company, reported the NIH’S National Institute of Allergy and Infectious Diseases (NIAID) has awarded grant funding worth up to $33 million to the company to support the development of a vaccine against the fungus Coccidioides, which causes Valley Fever.
An antibody that binds to the latent form of transforming growth factor-β1 (TGF-β1) prevented its release into the extracellular matrix and reduced the progression of fibrosis in the kidney. TGF-β is synthesized and secreted into the extracellular matrix in a latent inactive form associated with the latency peptide.